The FAST Global Summit & Gala draws more than 1,000 attendees from around the world. The annual event features a science summit, an education summit and an AAC carnival, and the weekend concludes with a star-studded gala recognized as Chicago’s largest celebrity fundraiser. Scroll down and click on the links below to watch presentations from the 2017 Summit, and remember to mark your calendar for the 2018 Summit, which kicks off Dec. 7.

FAST Science Summit [bookmark id=»science-summit»]

FAST’s Science Summit provides an opportunity to interact directly with the scientists, researchers, and pharmaceutical and biotechnology company leaders working on a cure for Angelman syndrome, while getting up to speed on all of the latest developments and breakthroughs in AS research.

AAV-mediated gene therapy to the central nervous system: prospect for Angelman syndrome

James M. Wilson, M.D., Ph.D., Rose H. Weiss professor and director, Orphan Disease Center; director, Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania

Gene therapy round table: ask the experts

Arthur L. Beaudet, M.D., Baylor College of Medicine
Scott Dindot, Ph.D., Texas A&M University
Kevin Nash, Ph.D., University of South Florida
David Segal, Ph.D., University of California, Davis
Edwin Weeber. Ph.D., University of South Florida
James M. Wilson, M.D., Ph.D., Penn Medicine’s Orphan Disease Center
Ashley Winslow, Ph.D., Penn Medicine’s Orphan Disease Center

Overview of the FAST research agenda for gene therapy and genetic editing in Angelman syndrome

Allyson Berent, DVM, DACVIM, chief science officer, FAST

The Global Angelman Syndrome Registry

Megan Cross, chair, FAST Australia
Chloe Simons, chief science officer, FAST Australia

Modifying the Bayley test to benefit clinical trials in Angelman syndrome

Anjali Sadhwani, Ph.D., clinical psychologist, Boston Children’s Hospital
Anne Wheeler, Ph.D., public health researcher, RTI International

Therapeutic development and outcome measure evaluation using a disease concept model in Angelman syndrome

Meagan Miller, Ph.D., discovery project leader, Roche

In the clinic: Ovid Therapeutics-OV101 and the engagement with the Angelman community

Jeremy Levin, D.Phil., MB BChir, chairman and chief executive officer, Ovid Therapeutics Inc.
Amit Rakhit M.D., MBA, chief medical and portfolio officer, Ovid Therapeutics Inc.

Approaching the clinic: nutritional support for patients with Angelman syndrome

Mike McCandless, founder, Disruptive Nutrition
Jessica Duis, M.D., M.S., assistant professor of pediatrics, Vanderbilt University Medical Center
Donna Herber, Ph.D., chief science officer, Disruptive Nutrition

AAV-mediated gene therapy approach: Ovid Therapeutics

Ed Weeber, Ph.D., Ph.D., professor, University of South Florida
Jenn Daley, Ph.D., director of research, Agilis Biotherapeutics

The Angelman Biomarkers and Outcome Measures Alliance (A-BOM)

Terry Jo Bichell, Ph.D., director, Angelman Biomarkers and Outcome Measures Alliance

Education Summit [bookmark id=»education-summit»]

The Education Summit provide parents, caregivers, therapists and educators with product demonstrations and information about services that can help improve the quality of life for individuals with Angelman syndrome – and those who care for them.

Introduction to augmentative and alternative communication (AAC)

Kelly Fonner, M.S., educational assistive technology trainer and consultant

Reading and writing in Angelman syndrome

Kelly Fonner, M.S., educational assistive technology trainer and consultant

Beginning communication is just a tool away – accessing multiple environments through assistive technology

Nancy Robinson, Ph.D., Communicative Disorders Program, San Francisco State University
Kathleen Sadao, Ed.D., educational consultant

Ask the experts panel

Kate Ahern, M.S.Ed.
Kelly Fonner, M.S.
Nancy Robinson, Ph.D.
Kathleen Sadao, Ed.D.

AAC vendor presentations

Prentke Romich Company (PRC), Saltillo and Tobii-Dynavox

Understanding anxiety and challenging behaviors in Angelman syndrome

Kate Ahern, M.S.Ed., assistive technology specialist

Augmentative and alternative communication (AAC) as an intervention to anxiety and challenging behaviors

Kate Ahern, M.S.
Shibvon Sargent, parent

Implementing strategies in the school placement panel

Amy Girouard, parent
Shari Holt, MHS, CCC-SLP
Danielle Williams, B.A., LBS1
Trish Brawley, B.A., LBS1